Mavens Biotech forms JV with Garuda Group for infra projects

Tissue culture plants and bio informatics  company Mavens Biotech Ltd said it signed a memorandum of understanding (MoU) with Bangalore-based Garuda Group to develop projects in real-estate, township development and other infrastructure related areas.

This joint venture (JV) has already identified three projects in and around the Bangalore city for the development of a mall, hotel cum convention centre and large township.

On Monday, Mavens Biotech shares increased 5% to Rs20 on the Bombay Stock Exchange, while the Sensex closed 1.2% higher at 18,081 points.

User

COMMENTS

RAVI SHANAKAR

6 years ago

GOOD TO SEE. ALL THE BEST.

GlaxoSmithKline Consumer Healthcare Q2 net profit rises to Rs71.8 crore

Gurgaon-based GlaxoSmithKline Consumer Healthcare Ltd said its net profit for second quarter ended 30 June 2010 increased to Rs71.8 crore from Rs55.1 crore a year ago.

During the April-June quarter, its total revenue increased to Rs552.5 from Rs486.3 crore, it said in a regulatory filing.

On Monday, GlaxoSmithKline Consumer shares ended 0.9% up to Rs1,785 on the Bombay Stock Exchange, while the Sensex closed 1.2% higher at 18,081 points.

User

India Cements Q1 net profit tumbles to Rs25 crore from Rs144.3 crore

India Cements Ltd said its first quarter net profit fell to Rs25 crore as against the net profit of Rs144.3 crore during the same quarter last year.

The company's total revenue decreased to Rs909.2 crore in the June 2010 quarter from Rs960.2 crore same quarter a year ago.

On Monday, India Cements shares ended 1.6% down to Rs104 on the Bombay Stock Exchange, while the Sensex closed 1.2% higher at 18,081 points.

User

We are listening!

Solve the equation and enter in the Captcha field.
  Loading...
Close

To continue


Please
Sign Up or Sign In
with

Email
Close

To continue


Please
Sign Up or Sign In
with

Email

BUY NOW

The Scam
24 Year Of The Scam: The Perennial Bestseller, reads like a Thriller!
Moneylife Magazine
Fiercely independent and pro-consumer information on personal finance
Stockletters in 3 Flavours
Outstanding research that beats mutual funds year after year
MAS: Complete Online Financial Advisory
(Includes Moneylife Magazine and Lion Stockletter)